CAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy manufacturing footprint in Europe. A 117,000 square-foot facility in Hoofddorp, the Netherlands, will be operational by 2020.
CAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR specialist MediGene by two new targets adding US$500m potential revenues to the licence agreement.
British drug maker AstraZeneca’s IL-5Ralpha blocker benralizumab did not reduce exacerbations significantly compared to placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2018-05-13_um_16.57.56.png594836Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-05-13 16:58:362018-05-13 16:58:36AZ COPD drug fails in Phase III study
A research team headed by Jean-Christophe Leroux from ETH Zurüch has created the first-ever 3-D printed mouth guard that could deliver drugs to the wearer and is highly customizable, in terms of drug release and design.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Online_TerryPizzie_CEO_Horizon.jpg450450h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-09 13:21:012018-05-09 13:21:01Horizon Discovery appoints Terry Pizzie as CEO
Americans and Europeans love fast food, even though doctors are now more certain than ever that the highly processed meals that go hand-in-hand with a hectic Western lifestyle are not a smart health choice. The latest findings suggest that fa(s)t food imprint key genes in the innate immune system, possibly causing the permanent immunological hypersensivity that is at the root of diabetes, atherosclerosis and other common diseases of civilisation.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-05-09 12:10:002024-04-02 16:21:23How fast food hijacks young genes
Following weeks of negotiations and four rejected bids, British neurology and orphan drug giant Shire has agreed to Takeda’s latest take-over offer of £46bn (€52,38bn).
Bayer today announced the selection of the new Executive Leadership Team for the Crop Science division, which will go into effect as of the closing of Bayer’s proposed acquisition of Monsanto. The closing is still subject to pending regulatory approval.
https://european-biotechnology.com/wp-content/uploads/2024/04/liamcondon.jpg500500h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-07 16:25:002018-05-07 16:25:00Bayer announces new Crop Science Leadership Team
Vas Narasimhan, the newly appointed CEO of Swiss pharma giant Novartis, introduced himself to the Swiss biotech industry with a stimulant talk at the Swiss Biotech Day. Apart from that participants of the annual gathering were in high spirits as the Swiss biotech sector continues to grow steadily.
Cell type switch helps colon cancer evade treatment
Latest NewsResearchers at LMU Munich have unraveled a new strategy of colon cancers to evade targeted therapies.
Kite expands cell therapy manufacturing in Europe
Latest NewsCAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy manufacturing footprint in Europe. A 117,000 square-foot facility in Hoofddorp, the Netherlands, will be operational by 2020.
bluebird bio expands US$1bn deal with MediGene
Latest NewsCAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR specialist MediGene by two new targets adding US$500m potential revenues to the licence agreement.
AZ COPD drug fails in Phase III study
Latest NewsBritish drug maker AstraZeneca’s IL-5Ralpha blocker benralizumab did not reduce exacerbations significantly compared to placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
3-D printed device delivers drugs in humans
Latest NewsA research team headed by Jean-Christophe Leroux from ETH Zurüch has created the first-ever 3-D printed mouth guard that could deliver drugs to the wearer and is highly customizable, in terms of drug release and design.
Horizon Discovery appoints Terry Pizzie as CEO
AppointmentsHorizon Discovery Group plc has announced the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.
How fast food hijacks young genes
BackgroundAmericans and Europeans love fast food, even though doctors are now more certain than ever that the highly processed meals that go hand-in-hand with a hectic Western lifestyle are not a smart health choice. The latest findings suggest that fa(s)t food imprint key genes in the innate immune system, possibly causing the permanent immunological hypersensivity that is at the root of diabetes, atherosclerosis and other common diseases of civilisation.
Shire accepts €52.4bn takeover bid by Takeda
Latest NewsFollowing weeks of negotiations and four rejected bids, British neurology and orphan drug giant Shire has agreed to Takeda’s latest take-over offer of £46bn (€52,38bn).
Bayer announces new Crop Science Leadership Team
AppointmentsBayer today announced the selection of the new Executive Leadership Team for the Crop Science division, which will go into effect as of the closing of Bayer’s proposed acquisition of Monsanto. The closing is still subject to pending regulatory approval.
Narasimhan embraces Swiss biotech industry
Latest NewsVas Narasimhan, the newly appointed CEO of Swiss pharma giant Novartis, introduced himself to the Swiss biotech industry with a stimulant talk at the Swiss Biotech Day. Apart from that participants of the annual gathering were in high spirits as the Swiss biotech sector continues to grow steadily.